Early Access — free while we kick the tires
EdgarHawk

Robert A Ortenzio

EXECUTIVE CHAIRMAN

Director Officer

Latest: Director selling · May 2026

3 filings analyzed · 2 companies · Latest 2026-06-02

Companies

Company Buys Sells Direction
Concentra Group Holdings Parent, Inc. CON 0 2 Net selling
SELECT MEDICAL HOLDINGS CORP SEM 0 1 Net selling

Activity

June 2026
Sell
130,000 shares
$3,250,026
Significance 4/10

Director Robert A Ortenzio sells 130,000 shares of CON at $25.00 for $3,250,026.00 under 10b5-1 plan.

Robert A Ortenzio, a director of Concentra Group Holdings Parent, Inc., sold 130,000 shares (130.0K shares) at $25.00 on 2026-06-01, reducing his holdings from 893,455 shares (893.5K shares) to 763,455 shares (763.5K shares), a -14.6% net change. This transaction is part of a pre-arranged 10b5-1 trading plan, meaning it was scheduled and not discretionary. The stock currently trades at $25.09, within its 52-week range of $18.54–$26.66. Concentra's fundamentals show solid underlying performance with Revenue of $569,555,000.00 (latest quarter), Net income of $50,488,000.00, annual revenue growth of +13.8%, and a P/E of 18.05. Since the sale was scheduled under a 10b5-1 plan rather than a discretionary choice, the transaction does not reflect a timing signal or conviction-driven decision by the insider.

May 2026
Sell
130,000 shares
$3,250,000
Significance 5/10

Director Robert A Ortenzio sells 130,000 shares for $3.25M, his 13th open-market sale in 36 months.

Robert A Ortenzio, a member of the board, disposed of roughly 12.7% of his Concentra holdings in a single transaction valued at $3.25 million—his thirteenth open-market sale over the past three years and a continuation of a consistent pattern of selling without any offsetting purchases. The timing is notable: the stock trades just slightly below its 52-week high and has gained ground over the past month, creating a backdrop where insiders might be inclined to take profits. Ortenzio's prior twelve sales all resulted in the stock declining within 90 days, suggesting a strong track record of well-timed exits; this latest sale extends that pattern. The company remains profitable with solid revenue growth and is trading at a reasonable valuation multiple, so this sale does not appear to signal financial distress—rather, it reflects a director systematically reducing his stake in what appears to be a fundamentally sound business.

November 2024
high
Sell
3,804,805 shares
$74,383,938
Significance 7/10

Executive Chairman ORTENZIO ROBERT A sells entire 3,804,805 share position in SEM for $74,383,937.75 on 2024-11-26

ORTENZIO ROBERT A liquidated his complete shareholding of 3,804,805 shares at $19.55, realizing $74,383,937.75 and reducing post-transaction holdings to 0 shares. The sale occurs after a significant drawdown: the stock has fallen -47.5% from its 52-week high of $40.20 and declined -35.7% over the prior 30 days and -41.5% over 90 days. At the same ticker (SEM), his prior 5 sales all generated positive 90-day returns (ranging from +13.3% to +26.3%), meaning the stock rose after each of those exits; his timing pattern at SEM shows 0 of 5 prior sells were well-timed, indicating these past sales preceded continued upside. The company's fundamentals remain intact: $1.8B in quarterly revenue, $55.6M net income, +5.2% annual revenue growth, and a 9.91 P/E ratio valued at $2.7B market cap. The full liquidation following severe price depreciation and the historical pattern of his prior SEM sales occurring before further gains raise questions about exit rationale given the underlying business health and valuation multiples.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access